CO5280032A1 - COMPOSICIONES RELACIONADAS CON ESTEAROIL-CoA DESATURASA HUMANA Y METODOS PARA TRATAR DESORDENES DE LA PIEL - Google Patents

COMPOSICIONES RELACIONADAS CON ESTEAROIL-CoA DESATURASA HUMANA Y METODOS PARA TRATAR DESORDENES DE LA PIEL

Info

Publication number
CO5280032A1
CO5280032A1 CO99051951A CO99051951A CO5280032A1 CO 5280032 A1 CO5280032 A1 CO 5280032A1 CO 99051951 A CO99051951 A CO 99051951A CO 99051951 A CO99051951 A CO 99051951A CO 5280032 A1 CO5280032 A1 CO 5280032A1
Authority
CO
Colombia
Prior art keywords
human
stearoyl
coa desaturase
expression
coa
Prior art date
Application number
CO99051951A
Other languages
English (en)
Inventor
Kurt Stenn
Stephen M Prouty
Parimoo Satish
Zhang Lin
Original Assignee
Johnson & Johnson Consumer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer filed Critical Johnson & Johnson Consumer
Publication of CO5280032A1 publication Critical patent/CO5280032A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con una molécula de ácido nucleico que codifica la estearoil-CoA desaturasa humana, y la proteína aislada modificada por la misma. Provee también un método de diagnóstico de un sujeto humano para un desorden de la piel caracterizado por un nivel anormal de expresión de estearoil-CoA desaturasa. Provee además un método para determinar si un agente aumenta el nivel de expresión de la estearoil-CoA desaturasa humana en las células de la piel que ya expresan la misma. Esta invención provee además métodos para determinar si un agente aumenta o disminuye el nivel de expresión o de actividad de la estearoil-CoA desaturasa humana en las células de la piel ya que expresan la misma. Esta invención provee además composiciones farmacéuticas para tratar desórdenes de la piel humana caracterizados por una expresión y/o actividad anormal de estearoil-CoA desaturasa, y métodos de tratamiento relacionados. Finalmente, esta invención provee anticuerpos relacionados, vectores para terapia génica, y ratones transgénicos.
CO99051951A 1998-08-14 1999-08-17 COMPOSICIONES RELACIONADAS CON ESTEAROIL-CoA DESATURASA HUMANA Y METODOS PARA TRATAR DESORDENES DE LA PIEL CO5280032A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9652098P 1998-08-14 1998-08-14

Publications (1)

Publication Number Publication Date
CO5280032A1 true CO5280032A1 (es) 2003-05-30

Family

ID=22257742

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99051951A CO5280032A1 (es) 1998-08-14 1999-08-17 COMPOSICIONES RELACIONADAS CON ESTEAROIL-CoA DESATURASA HUMANA Y METODOS PARA TRATAR DESORDENES DE LA PIEL

Country Status (4)

Country Link
AR (1) AR020190A1 (es)
AU (1) AU5774699A (es)
CO (1) CO5280032A1 (es)
WO (1) WO2000009754A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19955349A1 (de) * 1999-11-17 2001-08-02 Switch Biotech Ag Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
AU2001247228B2 (en) 2000-02-24 2007-01-18 Wisconsin Alumni Research Foundation Stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
US6686185B1 (en) 2000-03-07 2004-02-03 Millennium Pharmaceuticals, Inc. 25934, a novel fatty acid desaturase and uses therefor
US7232662B2 (en) 2000-09-26 2007-06-19 Xenon Pharmaceuticals Inc. Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5
WO2002040666A2 (en) * 2000-11-17 2002-05-23 Xenon Genetics Inc. Fat regulated genes, uses thereof, and compounds for modulating same
US7132529B2 (en) * 2001-07-30 2006-11-07 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
US20050043256A1 (en) 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
JP2005500857A (ja) 2001-08-29 2005-01-13 ゼノン ジェネティクス，インコーポレイテッド 脂肪酸合成酵素を用いたハイスループットスクリーニング分析
US20030219795A1 (en) * 2002-03-01 2003-11-27 Marcia Belvin SCDs as modifiers of the p53 pathway and methods of use
WO2004047746A2 (en) * 2002-11-21 2004-06-10 Bayer Pharmaceuticals Corporation Regulation of stearoyl-coa desaturase to treat obesity
FR2853910B1 (fr) * 2003-04-16 2007-08-24 Galderma Res & Dev Genes du psoriasis
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
CA2793423C (en) 2010-06-11 2015-09-15 Avon Products, Inc. Use of eclipta prostrata and other ppar-gamma inhibitors in cosmetics and compositions thereof
WO2012157736A1 (ja) 2011-05-19 2012-11-22 東レ株式会社 免疫誘導剤
WO2018008319A1 (ja) * 2016-07-08 2018-01-11 花王株式会社 核酸試料の調製方法
US20230242898A1 (en) * 2020-03-11 2023-08-03 Kao Corporation Method for preparing rna derived from skin surface lipids

Also Published As

Publication number Publication date
AR020190A1 (es) 2002-05-02
WO2000009754A2 (en) 2000-02-24
AU5774699A (en) 2000-03-06
WO2000009754A3 (en) 2000-08-24

Similar Documents

Publication Publication Date Title
CO5280032A1 (es) COMPOSICIONES RELACIONADAS CON ESTEAROIL-CoA DESATURASA HUMANA Y METODOS PARA TRATAR DESORDENES DE LA PIEL
Chiot et al. Modifying macrophages at the periphery has the capacity to change microglial reactivity and to extend ALS survival
Weihermann et al. Elastin structure and its involvement in skin photoageing
Frota Ruchon et al. Pex mRNA is localized in developing mouse osteoblasts and odontoblasts
Bogdanik et al. Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II/III spinal muscular atrophy
Rusconi et al. LSD1 modulates stress-evoked transcription of immediate early genes and emotional behavior
Fischer et al. The WldS gene modestly prolongs survival in the SOD1G93A fALS mouse
Properzi et al. Chondroitin 6‐sulphate synthesis is up‐regulated in injured CNS, induced by injury‐related cytokines and enhanced in axon‐growth inhibitory glia
Nishigori et al. Evidence that DNA damage triggers interleukin 10 cytokine production in UV-irradiated murine keratinocytes.
WO2020018461A1 (en) Compositions and methods of diagnosis and treatment for neurological diseases
Corrigan et al. The neuroprotective activity of the amyloid precursor protein against traumatic brain injury is mediated via the heparin binding site in residues 96‐110
DE60106763D1 (de) Glutaminsäure decarboxylase (gad) abgabesystem zur behandlung neurodegeneraliver erkrankungen
NZ507308A (en) Materials and methods for gene therapy
WO1998007850A3 (en) Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans
Pevida et al. Involvement of spinal chemokine CCL2 in the hyperalgesia evoked by bone cancer in mice: a role for astroglia and microglia
CY1107715T1 (el) Διαγνωση και αγωγη του καρκινου του προστατη
Klokov et al. Low dose IR-induced IGF-1-sCLU expression: a p53-repressed expression cascade that interferes with TGFβ1 signaling to confer a pro-survival bystander effect
Stassart et al. Axo‐glial interaction in the injured PNS
Ishiko et al. Chondroitinase injection improves keloid pathology by reorganizing the extracellular matrix with regenerated elastic fibers
Wang et al. Sciatic nerve regeneration in KLF7-transfected acellular nerve allografts
Ulrich et al. Expression profile of proteins involved in scar formation in the healing process of full‐thickness excisional wounds in the porcine model
KR20070112208A (ko) 편평상피세포암 관련 항원 발현의 억제에 의한 건선,편평상피세포암 및/또는 부전각화의 치료를 위한 방법 및의약 조성물
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
Buigues et al. Pathways and factors regulated by bone marrow-derived stem cells in human ovarian tissue
Benmaamar et al. Induced down‐regulation of neuropeptide Y‐Y1 receptors delays initiation of kindling

Legal Events

Date Code Title Description
FA Application withdrawn